MOUNTAIN VIEW, Calif., Feb. 22, 2011 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2010 after the NASDAQ Market closes on Monday, February 28, 2011.

The company will discuss financial results and provide a business update through a conference call and an audio webcast at 1:30pm PT on the same day.

Date: February 28, 2011

Time: 4:30 PM ET

Listen via Internet: http://ir.vivus.com/

Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=46450&k=1EEECE6B

Toll-free: 877-359-2916

International: 224-357-2386

A webcast replay will be available on the VIVUS web site for 30 days.

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA(R), has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US regulators. QNEXA(R) is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT:  VIVUS, Inc.          Timothy E. Morris, Chief Financial Officer          650-934-5200          The Trout Group          Investor Relations:          Brian Korb          646-378-2923          bkorb@troutgroup.com